Oviva, a digital provider of Type 2 diabetes treatment across Europe, has today announced its raised $21m in Series B funding.
The company has to date raised $34m and offers an evidence-based digital solution to stop the progression of and reverse Type 2 diabetes and obesity-related conditions. Its solution provides personalised support programmes based on good health, nutrition and lifestyle.
Patients receive tailored nutrition advice and personalised coaching via their phone.
The company said “Oviva’s technology-supported treatment has consistently demonstrated higher patient uptake, retention and outcomes at lower costs compared to face-to-face therapy. Oviva has treated 90,000 patients to-date across the UK, Germany, France, Switzerland and the UAE, consistently doubling each year for the last 3 years.”
Lucy Jones, Clinical Director, Oviva “Behaviour change is the safest and most cost-effective way of preventing and managing diet related health conditions including Type 2 diabetes. Our technology, empowers patients to take a leading role in managing their health, improves compliance and outcomes.”
Kai Eberhardt, CEO and Co-founder, Oviva “The new financing allows us roll out our uniquely effective solution to large patient populations rapidly across Europe and further develop the underlying technology to better address patients’ unmet needs.”
Christoph Ruedig, Partner at AlbionVC “Despite compelling evidence that digital treatments improve patient access and outcomes significantly while reducing costs for health systems, Europe is investing a fraction compared to the US in this area. We’re excited to continue to support Oviva’s accelerated roll out across Europe.”
Christoph Kausch from MTIP and Rainer Christine from Earlybird will be joining Oviva’s Board of Directors.
